- Home
- CRON vs XERS Comparison
CRON vs XERS Comparison
Compare CRON & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRON
- XERS
- Stock Information
- Founded
- CRON N/A
- XERS 2005
- Country
- CRON Canada
- XERS United States
- Employees
- CRON N/A
- XERS N/A
- Industry
- CRON Medicinal Chemicals and Botanical Products
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- CRON Health Care
- XERS Health Care
- Exchange
- CRON Nasdaq
- XERS Nasdaq
- Market Cap
- CRON 809.4M
- XERS 752.7M
- IPO Year
- CRON N/A
- XERS 2018
- Fundamental
- Price
- CRON $2.37
- XERS $7.68
- Analyst Decision
- CRON
- XERS Strong Buy
- Analyst Count
- CRON 0
- XERS 7
- Target Price
- CRON N/A
- XERS $6.79
- AVG Volume (30 Days)
- CRON 2.7M
- XERS 3.2M
- Earning Date
- CRON 08-07-2025
- XERS 08-07-2025
- Dividend Yield
- CRON N/A
- XERS N/A
- EPS Growth
- CRON N/A
- XERS N/A
- EPS
- CRON 0.05
- XERS N/A
- Revenue
- CRON $130,282,000.00
- XERS $246,025,000.00
- Revenue This Year
- CRON $27.65
- XERS $35.31
- Revenue Next Year
- CRON $5.63
- XERS $19.65
- P/E Ratio
- CRON $49.36
- XERS N/A
- Revenue Growth
- CRON 28.01
- XERS 35.62
- 52 Week Low
- CRON $1.60
- XERS $2.48
- 52 Week High
- CRON $2.77
- XERS $7.72
- Technical
- Relative Strength Index (RSI)
- CRON 58.17
- XERS 87.02
- Support Level
- CRON $1.93
- XERS $7.13
- Resistance Level
- CRON $2.77
- XERS $7.61
- Average True Range (ATR)
- CRON 0.13
- XERS 0.41
- MACD
- CRON 0.04
- XERS 0.21
- Stochastic Oscillator
- CRON 52.66
- XERS 98.60
About CRON Cronos Group Inc. Common Share
Cronos Group Inc headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S., the company has an option to acquire 5.9% of U.S. multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).